Alkermes (ALKS) Reports Q1 Earnings: What Key Metrics Have to Say

Alkermes (ALKS) Q1 Earnings and Revenues Miss Estimates

Alkermes Q1 2024 Earnings Preview

Analysts Are Bullish on These Healthcare Stocks: Atricure (ATRC), Alkermes (ALKS)

Deciphera Pharmaceuticals, Inc. (DCPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Deciphera Pharmaceuticals, Inc. (DCPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1

Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition?

Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition?

Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Ocular Therapeutix (OCUL)

Analysts Conflicted on These Healthcare Names: Enliven Therapeutics (ELVN), Alkermes (ALKS) and Apellis Pharmaceuticals (APLS)

Alkermes to Report First Quarter Financial Results on May 1, 2024

Alkermes (ALKS) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Alkermes (ALKS) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Analysts Offer Insights on Healthcare Companies: Catalent (CTLT), Vertex Pharmaceuticals (VRTX) and Alkermes (ALKS)

Hold Rating on Alkermes Amid Promising ALKS 2680 Data and Regulatory Challenges

Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study

Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study